12:00 AM
 | 
May 11, 2009
 |  BioCentury  |  Product Development

Conjoined against Conjunctivitis

By Mike Ward Senior Editor

Although treatment of allergic conjunctivitis is dominated by prescription antihistamines, generic steroids and over-the-counter products, Fovea Pharmaceuticals S.A. thinks its Prednisporin prednisolone/cyclosporine A combination will deliver enough improvement in symptom control and side effects to command premium pricing and capture 20% of the market.

The company last week unveiled Phase II data showing Prednisporin significantly reduced symptoms of allergic conjunctivitis at a tenth of the normal steroid monotherapy dose.

According to COO Pierre Belichard, about half the 80 million U.S. sufferers of allergic conjunctivitis use prescribed antihistamines or OTC products such as artificial tears, and another 10% use generic steroids. OTC products, directed at washing away surface antigens or countering histamine reactions, are not effective for more than half the patients who use them, he said.

"These therapies do not address the underlying chronic inflammation. The only...

Read the full 696 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >